ECMO use in cystic fibrosis with severe respiratory failure showed limited survival, highlighting the need for cautious ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Trained immunity in alveolar macrophages can lead to damaging lung inflammation, confirming the importance of context in this phenomenon.

Results come after positive results from a trial among people with idiopathic pulmomary disease.

Lung macrophages play a pivotal role in diseases like idiopathic pulmonary fibrosis. Two types of macrophages—the white blood ...

Pulmonary rehabilitation is initiated and completed by a greater proportion of patients with IPF vs COPD or other chronic respiratory disorders.

Panelists discuss how emerging, better-tolerated oral therapies for idiopathic pulmonary fibrosis (IPF) and progressive ...

Panelists discuss recent trial data demonstrating that a novel agent not only slows lung function decline but also delays ...

Puretech Health plc’s rollout May 20 of more phase IIb data with deupirfenidone (LYT-100) in idiopathic pulmonary fibrosis ...

GRI-0621 to be safe and well-tolerated in the first 12 and 24 patients evaluated, respectively Results on track for 6-week interim biomarker analysis (n=24) in July 2025 and topline data in Q3 2025 LA ...